The National Institutes of Health, the Banner Alzheimer's Institute, Genentech Inc. and the University of Antioquia in Colombia are collaborating on the first trial to evaluate a drug in the prevention of Alzheimer's disease (AD) among cognitively healthy individuals with a genetic risk of developing AD. The $100 million trial is the cornerstone of the Alzheimer's Prevention Initiative, a new international collaborative effort to accelerate the evaluation of promising but unproven...
The National Institutes of Health, the Banner Alzheimer's Institute, Genentech Inc. and the University of Antioquia in Colombia are collaborating on the first trial to evaluate a drug in the prevention of Alzheimer's disease (AD) among cognitively healthy individuals with a genetic risk of developing AD.
The $100 million trial is the cornerstone of the Alzheimer's Prevention Initiative, a new international collaborative effort to accelerate the evaluation of promising but unproven therapies for the prevention of AD.
The double-blind trial will evaluate crenezumab, an investigational anti-amyloid antibody, in approximately 300 people from a large extended family in Colombia who share a rare genetic mutation that typically triggers AD symptom onset at approximately age 45 years. The drug will also be evaluated in a smaller number of individuals in the United States. All participants will be aged 30 years or older with normal cognitive function at enrollment.
To avoid revealing the genetic status of the participants, most of whom do not want to know if they have the genetic mutation that increases their AD risk, the study will also include relatives who are noncarriers who will receive placebo.
The participants will receive injections of crenezumab or placebo at fixed intervals for up to five years. Researchers will use imaging techniques, cerebrospinal fluid tests and cognitive measures to monitor whether accumulation of amyloid and certain other proteins in the brain is reduced, whether brain size and function is maintained and whether mental performance is preserved.
The study will test the "amyloid hypothesis," which suggests that accumulation of the amyloid protein in the brain plays a key role in the progression of AD. Preclinical data indicate that crenezumab works by binding amyloid proteins and clearing them from the brain.
Genentech will contribute the majority of the funding for the trial, in addition to providing the study drug, as well as clinical and operational expertise.
Crenezumab is also currently being evaluated in a Phase II trial of patients with mild to moderate AD symptoms. The drug was selected for use in the prevention trial with guidance from an expert advisory panel.
Genentech is developing crenezumab in collaboration with Swiss biotech company AC Immune SA.
H. Lundbeck A/S said the New Drug Application (NDA) for Lu AA21004 in the treatment of adults with major depressive disorder (MDD) would be based on the positive outcomes recently observed in three Phase III trials of the drug.
Two of the trials were conducted in the United States and one was conducted primarily in Europe.
In one of the U.S.-based studies, 614 patients were randomized...
H. Lundbeck A/S and Takeda Pharmaceutical Co. Ltd.'s Lu AA21004, an investigational antidepressant, met the primary endpoint of a Phase III trial in which the compound was being evaluated as a treatment for major depressive disorder (MDD)...
The Food and Drug Administration sent Alexza Pharmaceuticals Inc. another complete response letter denying the company's request for approval of Adasuve (loxapine) inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Adasuve is a novel formulation of loxapine administered via...
MedImmune LLC, the biologics unit of AstraZeneca Plc, entered into a research collaboration and sublicense agreement with Axerion Therapeutics Inc., a privately held biotechnology firm based in Connecticut, to develop and commercialize a biologic approach to the treatment of Alzheimer's disease (AD).
Under the terms of the agreement,...